Halberd’s Disease Elimination Technology R&D at Youngstown State University (YSU) Draws Attention of CBS Affiliate WKBN
Jackson Center, Pennsylvania–(Newsfile Corp. – August 16, 2021) – Halberd Corporation’s (OTC Pink: HALB) research at Youngstown State University (YSU) caught the attention of Youngstown, OH TV news station, WKBN, a CBS affiliate. The station’s 5:00PM newscast on Friday, August 13, 2021, included a segment on Halberd’s on-going research and testing of its groundbreaking, patent protected technology at YSU, which could revolutionize disease treatment worldwide as, reported by Dave Sess. Watch the news segment and read the entire news story now!
Halberd’s current work at YSU, in conjunction with the work at Arizona State University (ASU) and GreenBioAZ, focuses on a unique methodology to eliminate the building blocks which are linked to the progression of Alzheimer’s Disease, PTSD and CTE (Chronic Traumatic Encephalopathy). Coincidentally, the same methodology is adaptable to the treatment of nearly all diseases. Halberd’s technology employs radio frequency and/or laser emissive energy exposure, to eliminate targeted disease antigens through a chemical bonding and extracorporeal (outside the body) process. This approach avoids exposure and side effects to the body from these eradication methodologies as it is performed extracorporeally. Dr. William Sturrus, Chair of the Physics, Astronomy, Geology, and Earth Sciences Department at YSU, is spearheading this portion of the research to establish proof of concept, and coordinating his efforts with Dr. Chen of GreenBioAZ and ASU.
Dr. Mitchell S. Felder, Chief Technology Officer of Halberd Corporation, referring to the Felder Doctrine (Physically remove the pathophysiologic basis of the disease) stated, “If you think about that sentence very carefully, you realize that (this method) beats any disease. This is almost instantaneous, versus intravenous antibiotics, in which it could take hours, to maybe even days, to kill the infectious pathogen. Here, (with Halberd’s methodology) you’re doing it almost instantaneously. In addition to being safer, by conducting disease eradication extracorporeally, the immediacy enhances efficacy by eliminating the disease target antigens before the destructive consequences are permitted to persist.”
William A. Hartman, Chairman, President & CEO, stated, “We thank YSU and WKBN for this informative session and for YSU’s hospitality in supporting this TV filming as well as our tour of YSU’s Technology Center. We particularly want to thank Dr. William Sturrus for working with Halberd Corporation, ASU, and GreenBioAZ since February in this exciting work which should revolutionize medicine worldwide. Our visit to YSU ended with an opportunity to meet and briefly discuss our exciting work with YSU President, Jim Tressel. Our thanks to the professionalism of the WKBN news team under Dave Sess and their efforts to bring public attention to our revolutionary medical research work being conducted at YSU.”
To get the latest news on Halberd’s exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
http://www.halberdcorporation.com
Twitter:@HalberdC
About Halberd Corporation.
Halberd Corporation (OTC Pink: HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies: Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.
Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.
The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.
The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.
We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/93207
